Details of the Drug

General Information of Drug (ID: DMZN5QX)

Drug Name

MGD014

Indication

Disease Entry	ICD 11	Status	REF
Human immunodeficiency virus-1 infection	1C62	Phase 1	[1]

Drug Type

Antibody

Cross-matching ID

TTD ID: DRI97M

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Human immunodeficiency virus Envelope glycoprotein gp160 (HIV env)	TTEC2T3	ENV_HV1H2	Inhibitor	[2]
T-cell surface glycoprotein CD3 (CD3)	TTUN7MC	NOUNIPROTAC	Inhibitor	[2]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

References

1	ClinicalTrials.gov (NCT03570918) MGD014 in HIV-Infected Individuals on Suppressive Antiretroviral Therapy. U.S. National Institutes of Health.
2	Clinical pipeline report, company report or official report of MacroGenics.
3	A phase I double blind, placebo-controlled, randomized study of a multigenic HIV-1 adenovirus subtype 35 vector vaccine in healthy uninfected adults. PLoS One. 2012;7(8):e41936.
4	A Phase 1 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 subtype C-modified vaccinia Ankara virus vaccine candidate in Indian volunteers. AIDS Res Hum Retroviruses. 2009 Nov;25(11):1107-16.
5	Company report (Inovio)
6	ClinicalTrials.gov (NCT00695877) Safety and Immune Response to a Recombinant Adenovirus HIV-1 Vaccine in Healthy Adults. U.S. National Institutes of Health.
7	GPG-NH2 acts via the metabolite alphaHGA to target HIV-1 Env to the ER-associated protein degradation pathway. Retrovirology 2010, 7:20.
8	2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
9	Mitigating the risk of cytokine release syndrome in a Phase I trial of CD20/CD3 bispecific antibody mosunetuzumab in NHL: impact of translational system modeling. NPJ Syst Biol Appl. 2020 Aug 28;6(1):28.
10	Clinical pipeline report, company report or official report of Genmab.
11	Clinical pipeline report, company report or official report of Y-mAbs Therapeutics.
12	Low-dose otelixizumab anti-CD3 monoclonal antibody DEFEND-1 study: results of the randomized phase III study in recent-onset human type 1 diabetes.Diabetes Care.2014 Oct;37(10):2746-54.
13	A Mucin 16 bispecific T cell-engaging antibody for the treatment of ovarian cancer. Sci Transl Med. 2019 Jun 19;11(497):eaau7534.
14	DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing. EBioMedicine. 2020 Feb;52:102625.
15	Clinical pipeline report, company report or official report of Ichnos Sciences.
16	Bispecific antibodies: a mechanistic review of the pipeline. Nat Rev Drug Discov. 2019 Aug;18(8):585-608.